{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:55:26Z","timestamp":1794264926740,"version":"4.9.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Increased fibroblast growth factor 23 (FGF23) related mosaic syndromes include a spectrum of disorders sharing postzygotic mutations, skin involvement and dysplastic bone lesions. This group encompasses both McCune Albright syndrome (MAS) and cutaneous-skeletal hypophosphatemia syndrome (CSHS). The altered production of FGF23 contributes to progression of the typical bone lesions of these disorders through a constant disruption of phosphate wasting and bone metabolism. In pediatric age, the current therapeutic strategies for fibrous dysplasia (FD) are able to control pain and reduce the entity of disability but not to improve disease course. FGF23 production is increased in MAS and negatively influences phosphate levels and bone metabolism. The availability of burosumab, an anti FGF23 antibody, introduced a potential new therapeutic tool for children with FD. A narrative review concerning the use of burosumab in MAS and CSHS was performed and the midterm outcome of treatment with burosumab in a 11-year-old patient with MAS and severe FD was described. The patient referred to our Center for periodic follow-up and treatment of severe FD. He was diagnosed with FD at the age of 1 year and 8 months and underwent four pathological fractures and two surgical interventions for correction of bone deformities. At the age of 5 years and 6 months, intravenous neridronate was started every 3 months with a partial improvement of bone pain and bone deformities. At the age of 8 years 9 months, subcutaneous periodic infusions of burosumab were started. Before treatment, laboratory assessment showed increased levels of FGF23 and alkaline phosphatase (ALP), and reduced phosphate with normal parathyroid hormone (PTH) levels. After 1 year of treatment with burosumab, a normalization of phosphate, ALP reduction, and normal to slightly increased PTH were observed. Nonetheless, a partial progression of FD was documented on periodic X-rays. Burosumab showed beneficial effects on bone tissue metabolisms in our patient without significant adverse effects but did not change FD course.<\/jats:p>","DOI":"10.3389\/fendo.2025.1577734","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:35Z","timestamp":1748232635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction"],"prefix":"10.3389","volume":"16","author":[{"given":"Alessandro","family":"Barbato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Vaiasuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Trinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Del Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero Igli","family":"Baroncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0969","article-title":"Diagnosis of endocrine disease: Mosaic disorders of FGF23 excess: Fibrous dysplasia\/McCune\u2013Albright syndrome and cutaneous skeletal hypophosphatemia syndrome","volume":"182","author":"de Castro","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00522","article-title":"Auxological and endocrinological features in children with mcCune albright syndrome: A review","volume":"11","author":"Tufano","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-018-0666-6","article-title":"Fibrous dysplasia for radiologists: beyond ground glass bone matrix","volume":"9","author":"Kushchayeva","year":"2018","journal-title":"Insights Imaging"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnz011","article-title":"Fibrous dysplasia\/mcCune-albright syndrome: A rare, mosaic disease of G\u03b1\u200as activation","volume":"41","author":"Boyce","year":"2020","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-013-3380-1","article-title":"Radiographic classification of coronal plane femoral deformities in polyostotic fibrous dysplasia","volume":"472","author":"Ippolito","year":"2014","journal-title":"Clin Orthop Relat Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/jamaoto.2017.2407","article-title":"Association of hearing loss and otologic outcomes with fibrous dysplasia","volume":"144","author":"Boyce","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3531","article-title":"Chiari I malformation and basilar invagination in fibrous dysplasia: prevalence, mechanisms, and clinical implications","volume":"33","author":"Pan","year":"2018","journal-title":"J Bone Mineral Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.06s224","article-title":"Fibrous dysplasia as a stem cell disease","volume":"21","author":"Riminucci","year":"2006","journal-title":"J Bone Mineral Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0751-z","article-title":"Regulation of phosphate homeostasis by the phosphatonins and other novel mediators","volume":"23","author":"Shaikh","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad671","article-title":"Serum phosphorus as a driver of skeletal morbidity in fibrous dysplasia","volume":"109","author":"Gun","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1546","article-title":"Mechanism of FGF23 processing in fibrous dysplasia","volume":"27","author":"Bhattacharyya","year":"2012","journal-title":"J Bone Mineral Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.0301262","article-title":"Fracture incidence in polyostotic fibrous dysplasia and the mcCune-albright syndrome","volume":"19","author":"Leet","year":"2004","journal-title":"J Bone Mineral Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000847","article-title":"Fibrous dysplasia in children and its management","volume":"31","author":"Gun","year":"2023","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"New Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-021-00657-z","article-title":"Denosumab treatment for giant cell tumors, aneurysmal bone cysts, and fibrous dysplasia\u2014Risks and benefits","volume":"19","author":"Pan","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-024-01250-z","article-title":"Burosumab efficacy and safety in patients with X-linked hypophosphatemia: systematic review and meta-analysis of real-world data","volume":"115","author":"Kiafzezi","year":"2024","journal-title":"Calcif Tissue Int"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ajmg.a.30915","article-title":"Skeletal changes in epidermal nevus syndrome: Does focal bone disease harbor clues concerning pathogenesis","author":"Heike","year":"2005","journal-title":"Am J Med Genet A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3702-8","article-title":"Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment","volume":"27","author":"Ovejero","year":"2016","journal-title":"Osteoporos Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/lmae037","article-title":"Patient-derived reference intervals for alkaline phosphatase to support appropriate utility for isoenzymes determinations and hypophosphatasia","volume":"55","author":"Joseph","year":"2024","journal-title":"Lab Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010034","article-title":"Reference intervals (RIs) of the bone turnover markers (BTMs) in children and adolescents: A proposal for effective use","volume":"13","author":"Brescia","year":"2024","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30426-7","article-title":"Approach to patients with hypophosphataemia","volume":"8","author":"Florenzano","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000184216","article-title":"Direct measurement of TP\/GFR: A simple and reliable parameter of renal phosphate handling","volume":"44","author":"Stark","year":"1986","journal-title":"Nephron"},{"key":"B25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Horm Res Paediatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116004","article-title":"Burosumab treatment for fibrous dysplasia","volume":"150","author":"Gladding","year":"2021","journal-title":"Bone"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000527129","article-title":"Burosumab therapy in a paediatric patient with mcCune-albright syndrome: A case report","volume":"96","author":"Apperley","year":"2023","journal-title":"Horm Res Paediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.CC.24.00279","article-title":"Improvement of fibrous dysplasia after burosumab therapy in a pediatric patient with mcCune-albright syndrome","volume":"14","author":"Sawamura","year":"2024","journal-title":"JBJS Case Connect"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.866831","article-title":"A case report: first long-term treatment with burosumab in a patient with cutaneous-skeletal hypophosphatemia syndrome","volume":"13","author":"Merz","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116598","article-title":"The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome","volume":"166","author":"Sugarman","year":"2023","journal-title":"Bone"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101138","article-title":"Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report","volume":"15","author":"Khadora","year":"2021","journal-title":"Bone Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101605","article-title":"A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets","volume":"17","author":"Huynh","year":"2022","journal-title":"Bone Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2023.101725","article-title":"Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome","volume":"20","author":"Abebe","year":"2024","journal-title":"Bone Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae184","article-title":"Burosumab, a transformational treatment in a pediatric patient with cutaneous-skeletal hypophosphatemia syndrome","volume":"2","author":"da Silva","year":"2024","journal-title":"JCEM Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.99.P249","article-title":"Burosumab treatment for FGF23-related hypophoshatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome. 26th European Congress of Endocrinology Stockholm (Sweden 11 May 2024\u201314 May 2024) ECE 2024\u201399 P249 (Abstract)","author":"Stelmachowska-Bana\u015b","year":"2024","journal-title":"Endocrine Abstracts"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.025","article-title":"Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients","volume":"127","author":"DeLacey","year":"2019","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117324","article-title":"Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment","volume":"190","author":"Padidela","year":"2025","journal-title":"Bone"},{"key":"B41","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ando.2023.07.108","article-title":"Hyperparathyroidism after three years of burosumab in children affected with x-linked hypophosphatemia","volume":"84","author":"Zhukouskaya","year":"2023","journal-title":"Annales d'Endocrinologie"},{"key":"B42","first-page":"1","article-title":"CRYSVITA II-35-G-Summary of product characteristics","year":"2018"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1577734\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:10:36Z","timestamp":1748232636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1577734\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":42,"alternative-id":["10.3389\/fendo.2025.1577734"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1577734","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"article-number":"1577734"}}